A Year of Freedom: New Diabetes System Aims for 'Set-and-Forget' Care

GERMANTOWN, MD – January 08, 2026 – For millions of people living with type 1 diabetes, the daily routine of device management is a relentless, unavoidable burden. Today, that burden may have gotten significantly lighter. Senseonics and Sequel MedTech have announced that the first commercial patients are now using a groundbreaking integrated system that pairs the world's only one-year implantable continuous glucose monitor (CGM) with an automated insulin delivery (AID) system.

This launch combines Senseonics' Eversense 365 CGM with Sequel MedTech’s twiist™ Automated Insulin Delivery (AID) system, creating a first-of-its-kind solution in diabetes technology. The integration represents a major milestone in the quest for a more 'hands-off' approach to diabetes management, aiming to shift focus from constant device interaction to long-term, automated care. Broad availability of the integrated system is expected by March 2026.

“While our technologies are unique, our goal is the same - to improve lives and reduce complexity for patients living with diabetes,” said Tim Goodnow, President and CEO of Senseonics, in a statement. “Patients and providers want reliable, long-term automated glucose readings and we’ve taken a major step forward in simplifying and personalizing diabetes management.”

A New Era of Convenience

The central promise of this new system is unprecedented convenience. The Eversense 365 CGM features a small sensor that is implanted under the skin of the upper arm by a healthcare provider in a brief in-office procedure. This single sensor then provides continuous glucose data for a full 365 days. A small, removable smart transmitter is worn on the skin over the sensor, which sends glucose readings to a mobile app every five minutes.

This year-long duration stands in stark contrast to the current standard of care. Competing CGM systems from major players like Dexcom and Abbott require users to change their externally worn sensors every 10 to 15 days. Medtronic's sensors typically last for 7 days. For patients, this means dozens of sensor changes per year, each carrying the risk of insertion errors, site irritation, or adhesive failure. The Eversense 365 reduces this to a single annual event.

For users, the potential quality-of-life improvements are substantial. The reduction in device maintenance could lessen the significant psychological and physical burden of managing a chronic condition. From a provider's perspective, the long-term, implantable nature of the device may dramatically improve patient adherence, a key factor in achieving better long-term health outcomes and reducing costly diabetes-related complications.

Under the Hood: The Technology Driving the Change

This new system is more than just a long-lasting sensor; it's the synergy between two distinct, advanced technologies. While the Eversense 365 provides the crucial glucose data, the twiist AID system uses that data to make automated treatment decisions.

The twiist system, which received FDA clearance in March 2024, is an insulin pump powered by a sophisticated algorithm called the twiist Loop. This algorithm analyzes real-time glucose readings and predictive trends to automatically adjust insulin delivery, working to prevent both high and low blood sugar events with minimal user input.

What sets the twiist pump apart is its proprietary iiSure™ technology. According to Sequel MedTech, this feature directly measures the volume of insulin being delivered with each dose. This allows the system to detect an occlusion, or blockage in the insulin flow, up to nine times faster than other systems that rely on indirect pressure sensors. Faster occlusion detection is a critical safety feature, as an undetected blockage can quickly lead to hyperglycemia and potentially dangerous complications like diabetic ketoacidosis (DKA).

“Diabetes management is deeply personal, and no single approach works for everyone,” noted Alan Lotvin, CEO of Sequel MedTech. “Our focus on personalization means Sequel is committed to creating choice for people living with diabetes; integration with the Eversense CGM is an important step in this journey.”

Navigating a Crowded and Competitive Market

The Senseonics and Sequel partnership enters a fiercely competitive diabetes technology landscape. The market for integrated AID systems is dominated by established giants like Medtronic with its MiniMed 780G system, Tandem Diabetes Care with its t:slim X2 pump (which pairs with Dexcom CGMs), and Insulet's popular tubeless Omnipod 5 system.

These systems have proven their ability to improve glycemic control, significantly increasing users' Time in Range—the percentage of time spent within the target blood glucose level. They have built loyal user bases and strong relationships with insurers and healthcare systems. To compete, any new entrant must offer a compelling and distinct advantage.

The one-year sensor life is precisely that advantage. While competitors have focused on improving algorithms and creating smaller, more accurate external devices, Senseonics has carved out a unique niche by tackling the problem of wear-time. This 'set-and-forget' aspect may appeal strongly to patients experiencing device fatigue or those who desire a more discreet solution.

Interestingly, Sequel MedTech is pursuing a strategy of broad compatibility. In March 2025, the company also announced a partnership to integrate the twiist system with Abbott's FreeStyle Libre 3 Plus sensor, a 15-day CGM from one of the market's largest players. This dual-partnership approach allows the twiist pump to serve both the large existing market of short-term sensor users and the emerging market for long-term implantable solutions.

The Path to Patients: Approval, Access, and Financial Realities

Bringing this integrated system to market was a multi-step regulatory process. A key milestone was the FDA's clearance of Eversense 365 as an integrated CGM (iCGM) in September 2024, which officially permitted its use as part of an AID system. With the twiist pump already cleared, the pathway was open for this commercial launch.

Now, the focus shifts to access and reimbursement. While the first patients are now using the system, achieving broad coverage from major insurance providers is the next critical hurdle. The cost-effectiveness argument will be central. Payers will need to weigh the potentially higher upfront cost of an implantable system against the potential long-term savings from improved patient adherence, better health outcomes, and fewer hospitalizations.

For Senseonics, this launch is a pivotal moment. The company has demonstrated strong revenue growth but has struggled with profitability. The success of the integrated Eversense 365 system is crucial to its strategy for capturing a larger share of the multi-billion-dollar glucose monitoring market and achieving financial stability. The positive investor reaction, with Senseonics' stock (NASDAQ: SENS) seeing a significant jump following the news, indicates optimism that its unique value proposition will resonate in the marketplace.